RxDoctor Payments Data

McKenzie Peet

Physician Assistant · Tulsa, OKNPI 1790336642

Payments from drug & device makers

$971in general payments, 2019–2025

Across 39 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$247
  • Medtronic$144
  • Teleflex LLC$110
  • AbbVie$103
  • Sumitomo Pharma America, Inc.$75
  • Urovant Sciences Inc$51
  • plus $241 from 8 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971 in reported general payments places this provider in the 70th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,483
Medicare patients
227
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron222$146,749
MyrbetriqMirabegron25$16,762
ElmironPentosan Polysulfate Sodium11$11,002
Estradiol47$2,342
Methenamine Hippurate31$1,591
Solifenacin Succinate24$1,586
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$1,480
Tamsulosin Hcl140$1,297
Oxybutynin Chloride ErOxybutynin Chloride44$936
Tolterodine Tartrate ErTolterodine Tartrate26$701
Finasteride51$608
NitrofurantoinNitrofurantoin Macrocrystal20$536
Cephalexin14$131
Ciprofloxacin Hcl15$63
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$75$146,749222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →